Novel Mutations on EGFR Leu792 Potentially Correlate to Acquired Resistance to Osimertinib in Advanced NSCLC
Authors:
- 1 June 2017
- journal article
- case report
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 12 (6) , e65-e68
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- L718Q Mutation as New Mechanism of Acquired Resistance to AZD9291 in EGFR -Mutated NSCLCJournal of Thoracic Oncology, 2016
- The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment StrategiesClinical Cancer Research, 2015
- EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR InhibitorsClinical Cancer Research, 2015
- Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790MNature Medicine, 2015
- AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung CancerNew England Journal of Medicine, 2015
- AZD9291, an Irreversible EGFR TKI, Overcomes T790M-Mediated Resistance to EGFR Inhibitors in Lung CancerCancer Discovery, 2014
- Coexistence of EGFR with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a comprehensive mutation profiling from 5125 Chinese cohortsBritish Journal of Cancer, 2014
- Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR InhibitorsScience Translational Medicine, 2011